Your browser doesn't support javascript.
loading
The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
Knipe, Rachel S; Tager, Andrew M; Liao, James K.
Affiliation
  • Knipe RS; Pulmonary and Critical Care Unit and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (R.S.K., A.M.T.); and Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois (J.K.L.).
  • Tager AM; Pulmonary and Critical Care Unit and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (R.S.K., A.M.T.); and Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois (J.K.L.).
  • Liao JK; Pulmonary and Critical Care Unit and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (R.S.K., A.M.T.); and Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois (J.K.L.) jliao@medicine.bsd.uchicago.edu.
Pharmacol Rev ; 67(1): 103-17, 2015.
Article in En | MEDLINE | ID: mdl-25395505
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Signal Transduction / Protein Kinase Inhibitors / Rho-Associated Kinases / Idiopathic Pulmonary Fibrosis / Molecular Targeted Therapy / Lung Limits: Animals / Humans Language: En Journal: Pharmacol Rev Year: 2015 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Signal Transduction / Protein Kinase Inhibitors / Rho-Associated Kinases / Idiopathic Pulmonary Fibrosis / Molecular Targeted Therapy / Lung Limits: Animals / Humans Language: En Journal: Pharmacol Rev Year: 2015 Type: Article